HLS Therapeutics Inc.
HLTRF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | 0.28 | -0.12 | 0.19 |
| FCF Yield | 1.84% | 3.04% | 3.41% | 3.73% |
| EV / EBITDA | 40.45 | 33.76 | 51.16 | 28.05 |
| Quality | ||||
| ROIC | -1.13% | -0.67% | -1.61% | -2.19% |
| Gross Margin | 81.22% | 82.32% | 81.00% | 82.72% |
| Cash Conversion Ratio | -0.63 | -1.68 | -0.80 | -1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.88% | -3.38% | -2.72% | -2.74% |
| Free Cash Flow Growth | -37.53% | -0.14% | 10.34% | 112.66% |
| Safety | ||||
| Net Debt / EBITDA | 10.77 | 9.21 | 15.76 | 10.22 |
| Interest Coverage | -0.56 | -0.45 | -1.09 | -1.32 |
| Efficiency | ||||
| Inventory Turnover | 0.36 | 0.37 | 0.32 | 0.30 |
| Cash Conversion Cycle | -68.73 | 3.00 | 10.63 | 55.27 |